Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups.
Cheifetz AS, Melmed GY, Spiegel B, Talley J, Devlin SM, Raffals L, Irving PM, Jones J, Kaplan GG, Kozuch P, Sparrow M, Velayos F, Baidoo L, Bressler B, Siegel CA. Cheifetz AS, et al. Among authors: kaplan gg. Inflamm Bowel Dis. 2012 Dec;18(12):2294-300. doi: 10.1002/ibd.22920. Epub 2012 Feb 15. Inflamm Bowel Dis. 2012. PMID: 22337359
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel JF, Gearry R; International Organization for Study of Inflammatory Bowel Diseases. Ananthakrishnan AN, et al. Among authors: kaplan gg. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):666-678. doi: 10.1016/S2468-1253(22)00021-8. Epub 2022 Apr 27. Lancet Gastroenterol Hepatol. 2022. PMID: 35487235 Review.
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R. Ma C, et al. Among authors: kaplan gg. Aliment Pharmacol Ther. 2017 May;45(9):1232-1243. doi: 10.1111/apt.14016. Epub 2017 Mar 2. Aliment Pharmacol Ther. 2017. PMID: 28252210
Assessment of variables associated with smoking cessation in Crohn's disease.
Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, Cohen RD, Devlin SM, Panaccione R, Hanauer SB, Rubin DT. Leung Y, et al. Among authors: kaplan gg. Dig Dis Sci. 2012 Apr;57(4):1026-32. doi: 10.1007/s10620-012-2038-2. Epub 2012 Feb 7. Dig Dis Sci. 2012. PMID: 22311366
Novel concepts in inflammatory bowel disease.
Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Moran GW, et al. Among authors: kaplan gg. Br Med Bull. 2014;109:55-72. doi: 10.1093/bmb/ldt039. Epub 2014 Feb 5. Br Med Bull. 2014. PMID: 24505093 Review.
Use of combination therapy in IBD.
Kaplan G, Panaccione R. Kaplan G, et al. Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S219-21. doi: 10.1002/ibd.20688. Inflamm Bowel Dis. 2008. PMID: 18816768 No abstract available.
Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE, Benchimol EI, Bernstein CN, Singh H, Lix L, Tennakoon A, Leung S, Aviña A, Coward S, Jones J, Kaplan G, Murthy SK, Nguyen GC, Peña-Sánchez JN. Targownik LE, et al. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1788-1798.e2. doi: 10.1016/j.cgh.2018.11.003. Epub 2018 Nov 15. Clin Gastroenterol Hepatol. 2019. PMID: 30448599
405 results